Teva Pharmaceutical Industries (TEVA) PT Set at $20.00 by UBS Group

UBS Group set a $20.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research note published on Monday, December 18th, thefly.com reports. The firm currently has a hold rating on the stock.

Other research analysts have also recently issued reports about the company. BTIG Research raised their target price on Teva Pharmaceutical Industries to $20.00 in a research note on Friday, December 15th. Gabelli restated a buy rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. ValuEngine upgraded Teva Pharmaceutical Industries from a hold rating to a buy rating in a research note on Monday, October 2nd. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the company a buy rating in a research note on Wednesday, October 25th. Finally, Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $20.00 price objective for the company in a research report on Friday, December 15th. Eight equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $21.17.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.33 during midday trading on Monday, hitting $22.07. The company’s stock had a trading volume of 40,555,440 shares, compared to its average volume of 25,730,000. The company has a market capitalization of $21,730.00, a PE ratio of -3.76, a PEG ratio of 1.36 and a beta of 0.54. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

Large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its stake in Teva Pharmaceutical Industries by 7.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock valued at $8,025,000 after acquiring an additional 17,116 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Teva Pharmaceutical Industries by 37.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 33,430 shares of the company’s stock valued at $1,111,000 after acquiring an additional 9,136 shares in the last quarter. Blair William & Co. IL lifted its stake in Teva Pharmaceutical Industries by 3.2% in the 2nd quarter. Blair William & Co. IL now owns 77,615 shares of the company’s stock valued at $2,578,000 after acquiring an additional 2,372 shares in the last quarter. BB&T Securities LLC lifted its stake in Teva Pharmaceutical Industries by 82.1% in the 2nd quarter. BB&T Securities LLC now owns 19,313 shares of the company’s stock valued at $641,000 after acquiring an additional 8,708 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its stake in Teva Pharmaceutical Industries by 1.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock valued at $1,416,000 after acquiring an additional 611 shares in the last quarter. Institutional investors and hedge funds own 51.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://ledgergazette.com/2018/01/13/ubs-analysts-give-teva-pharmaceutical-industries-teva-a-20-00-price-target.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply